Celltrion said Wednesday it expects to post record-high earnings for the fourth quarter of 2025, raising expectations that its annual operating profit will grow 137 percent year-on-year to surpass the 1 trillion won ($693 million) mark for the first time in its history. The biopharmaceutical firm released its earnings guidance for the fourth quarter, projecting 1.28 trillion won in sales and 472.2 billion won in operating profit. The figures represent year-on-year growth of 20.7 percent in sales and 140.4 percent in operating profit, marking the company’s highest-ever quarterly earnings. The operating margin also reaches 36.8 percent. If the figures are confirmed after an auditors’ review, the company’s annual sales would reach 4.12 trillion won, up 15.7 percent year-on-year, while operating profit would stand at 1.17 trillion won, up 136.9 percent from a year earlier. This would mark the first time that annual revenue tops 4 trillion won and operating profit surpasses 1 trillion won. Celltrion attributed the brisk numbers to rapid growth in global sales of its new high-value produ